RT Journal Article
SR Electronic
T1 Moxonidine for tramadol withdrawal symptoms during detoxification
JF BMJ Case Reports
FD BMJ Publishing Group Ltd
SP bcr2015210444
DO 10.1136/bcr-2015-210444
VO 2015
A1 Talih, Farid
A1 Ghossoub, Elias
YR 2015
UL http://casereports.bmj.com/content/2015/bcr-2015-210444.abstract
AB It is well documented in the literature that noradrenergic pathways are key in the manifestation of opioid withdrawal symptoms, which is why clonidine is used as an off-label agent in opioid detoxification regimens given its anti-sympathetic properties. Moxonidine is a selective I1-imidazoline receptor agonist, similar to clonidine but with no α2-adrenergic agonist activity and subsequently fewer side effects. We report the case of a 33-year-old woman with a 15-year history of tramadol use who was admitted voluntarily for detoxification. She was started on moxonidine and had an uneventful detoxification. Two months after discharge, the patient maintained tramadol abstinence with good tolerability to moxonidine. To the best of our knowledge, this has not been previously reported in the medical literature.